- STN-DBS improves motor functions and daily living for Parkinson's patients.
- Improvements were 51% at year 1, declining to 36% at year 5.
- Dyskinesia scores decreased by 75% at year 1.
- Serious adverse events included infections, with 9 cases reported.
- 94% of patients reported satisfaction at 5 years despite adverse events.
- Study involved 313 patients over 23 US centers.
- Eligibility required at least 5 years of idiopathic Parkinson's disease.
- Studied the impact of advancing DBS technologies.
Source: JAMA Neurology
